GENE ONLINE|News &
Opinion
Blog

2020-10-19| Asia-PacificCOVID-19

Philippines Says Phase 3 Trial of Sinovac’s CoronaVac May Start in November

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

China-based Sinovac Biotech may initiate a Phase 3 clinical trial of its inactivated COVID-19 vaccine, CoronaVac, in the Philippines as early as next month. Philippine FDA Commissioner Eric Domingo said that a formal application from the company is expected within two weeks. If it passes the review process, which will take about 21 days, the trial will start in November at the earliest. Without mentioning the timeframe, a spokesperson of Sinovac mentioned that the company has provided materials to relevant officials in the Philippines and hopes to start the Phase 3 trial as soon as possible.

 

CoronaVac

CoronaVac’s Phase 1/2 double-blinded, randomized clinical trial was approved by the National Medical Products Administration (NMPA) of China on August 10. The trial is expected to recruit adolescents and children between the ages of 3 and 17 to administer low-dose (300SU/dose) and medium-dose (600SU/dose) with an interval of 28 days.

On the other hand, the company also recruited 18 to 59-year-old adults and the elderly over 60 years old in Jiangsu and Hebei for the Phase 1/2 clinical trial of CoronaVac. The results demonstrated that the subjects’ seroconversion rates are higher than 90%, and there are no serious adverse reactions related to the vaccine.

Unlike the DNA or RNA vaccine candidates, CoronaVac is based on an inactivated pathogen. The attenuated virus loses the ability to replicate, and it is produced with an adjuvant. Due to the traditional manufacturing method, the inactivated virus vaccine can only induce a humoral immune response. If the manufacturing process is not handled properly, the virus may still pose a risk of spreading the disease.

 

Testing of Vaccine Candidates from China and Russia

As the country with the highest number of infections in Southeast Asia, the Philippines is also evaluating COVID-19 vaccines of Russia’s Gamaleya Research Institute and Johnson & Johnson’s Janssen. Besides, it is also in contact with Pfizer and Moderna. In July, Philippine President Rodrigo Duterte made a plea to Chinese President Xi Jinping with hopes that the Philippines could become the first wave of beneficiaries after China successfully produced COVID-19 vaccines. Duterte also authorized Manila to purchase vaccines from Southeast Asian countries. On October 15th, he reiterated the Philippines’ desire to introduce COVID-19 vaccines developed by China or Russia.

In addition to the COVID-19 vaccine, Sinovac’s main vaccine product line includes enterovirus71 (EV71), hepatitis A, hepatitis B, seasonal influenza, and quadrivalent influenza (Quadrivalent Influenza vaccine, QIV). Besides, there are vaccines for H5N1 poultry, Influenza (H5N1 pandemic influenza, avian flu), H1N1 influenza (H1N1 influenza, swine flu), tetanus, and mumps.

Related Article: After AZ, Another Big Pharma Halts COVID-19 Vaccine Trial Due to Patient Illness

References
  1. https://www.reuters.com/article/us-health-coronavirus-philippines-sinova/philippines-eyes-sinovac-trial-as-early-as-november-idUSKBN2700TJ

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
AstraZeneca’s COVID-19 Vaccine Finally Wins Full Authorization in the European Union
2022-11-01
LATEST
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
2022-11-24
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moving Past Animal Models with Better Data for Drug Discovery
2022-11-23
IonOpticks ushers in a new age of proteomics with Aurora Frontier
2022-11-23
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!